Genmab — Oktober 2018
-
Det New York-baserede finanshus H.C. Wainwright indleder dækning af Genmab-aktien på baggrund af kræftmidlet Darzalex, hvor markedet afventer data fra det meget vigtige fase 3 studie, Maia. Finanshuset indleder dækning med anbefalingen "køb" og et kursmål på 1600 kr.
H.C. Wainwright forventer, at Darzalex fortsat vil levere solid vækst mange år endnu, skriver finanshuset i en analyse. Det noterer sig samtidig, at Genmab modtager royalties fra sin partner Johnson and Johnson, og finanshuset esti -
Et gensyn med en dejlig historie http://tv.tv2.dk/2015-10-22-kraeften-var-uhelbredelig-nu-har-dansk-kur-stoppet-ullas-kraeftceller
-
H.C. Wainwright Analysts Earn Number One Rankings in 2017 Thomson Reuters Analyst Awards https://www.businesswire.com/news/home/20170724005355/en/H.C.-Wainwright-Analysts-Earn-Number-Rankings-2017
-
Lad os alle bede til at den holder 1020 i luk..:-)
-
Det lykkedes...
-
Rare manufacturing glitch raises concern over CAR-T therapies: study https://in.reuters.com/article/us-novartis-kymriah/rare-manufacturing-glitch-raises-concern-over-car-t-therapies-study-idINKCN1MB334?feedType=RSS&feedName=health&utm_source=Twitter&utm_medium=Social&utm_campaign=Feed%3A+reuters%2FINhealth+(News+%2F+IN+%2F+Health)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind